Oncologist-approved cancer information from the American Society of Clinical Oncology
Printer Friendly
Download PDF

Parathyroid Cancer

This section has been reviewed and approved by the Cancer.Net Editorial Board, 11/2013
Statistics

ON THIS PAGE: You will find information about how many people learn they have this type of cancer each year and some general survival information. Remember, survival rates depend on several factors. To see other pages in this guide, use the colored boxes on the right side of your screen, or click “Next” at the bottom.

Parathyroid cancer is quite rare. Most tumors that develop in the parathyroid gland are benign, with parathyroid cancer accounting for less than 100 cases per year in the United States. Men and women are equally affected by parathyroid cancer, which generally occurs in middle age.

The five-year survival rate is the percentage of people who survive at least five years after the cancer is detected, excluding those who die from other diseases. The five-year survival rate of people with parathyroid cancer is 89%, and the ten-year survival rate is 49%.

Cancer survival statistics should be interpreted with caution. These estimates are based on data from many people with this type of cancer in the United States, but the actual risk for a particular individual may differ. It is not possible to tell a person how long he or she will live with parathyroid cancer. Because the survival statistics are measured in multi-year intervals, they may not represent advances made in the treatment or diagnosis of this cancer.

Learn more about understanding statistics.

Sources: American Cancer Society and Lawrence Kim, MD, "Parathyroid Carcinoma,"eMedicine, http://emedicine.medscape.com/article/280908-overview - a0199. Updated 11 September 2013.

Choose “Next” (below, right) to continue reading this guide, or use the colored boxes located on the right side of your screen to visit any section.

Last Updated: 
Friday, March 21, 2014

© 2005-2014 American Society of Clinical Oncology (ASCO). All rights reserved worldwide.

Connect With Us: